TCT 2019 | EURO-CTO: Results at 3 Years of CTO Recanalization vs. Optimal Medical Treatment

Courtesy of SBHCI.

Between 16 and 18% of coronary artery lesions in patients with chronic stable CAD are chronic total occlusions (CTO). CTO revascularization could benefit symptomatic patients, but it remains unclear whether such complex procedure is safe in the long run, given the study outcomes on PCI in CAD so far. 

Highlights TCT 2019

This study presented at the scientific sessions of TCT 2019 randomized multivessel patients with at least one CTO to DES stenting on severe lesions and further functional ischemia assessment vs. optimal medical treatment. 

The study included 407 patients from 26 centers and 8 countries to recanalization plus optimal medical treatment (OMT) (n=259) vs OMT alone (n=137). Both successful CTO intervention + OMT and OMT alone patients were assessed with a functional test at 12 and 36 months. 

There were no differences in hard end points (infarction or death) between the groups, but patients with successful recanalization did present better quality of life, less frequent angina, better functional class and less physical limitation. 

18.2% of OMT patients and 7.3% of PCI + OMT patients needed new ischemia driven revascularization after 3 years. 

Conclusion

This study is the first to show a benefit of PCI over OMT in symptomatic CTO patients. There was significant event reduction in the PCI group basically driven by symptom improvement and better rate of re

Courtesy of SBHCI.

Link to the SBHCI publication HERE

euro-cto

Original Title: EURO-CTO: 3-Year Outcomes From a Randomized Trial of PCI vs. Medical Therapy in Patients With Chronic Total Coronary Occlusions.

Author of the Original Article: Gerald S. Werner.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...